2015 Rheumatology Year in Review
Was 2015 a good year for psoriasis, IL-17, biosimilars, narcotics, the ACR and gout? Our year end review discusses the most impactful news and research from the last 12 months.
Was 2015 a good year for psoriasis, IL-17, biosimilars, narcotics, the ACR and gout? Our year end review discusses the most impactful news and research from the last 12 months.
Rheumatoid arthritis affects women in their child-bearing years and many will face the issue of pregnancy and RA management at some point. Here are11 considerations for those managing RA patients who wish to become pregnant.
While decades of drug development have improved treatment options, some of our older drugs are harder to improve upon. The same can be said for old movies and new movies, or classic literature and current best sellers. Which do you prefer or rely on?
Discussions on drug safety can be as treacherous as quicksand for the patient and physician. What the physician knows and what the patient perceives may not be in sync.
Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.
Rheumatoid arthritis affects women in their child-bearing years and many will face the issue of pregnancy and RA management at some point. Here are11 considerations for those managing RA patients who wish to become pregnant.
Dr. Schwartzman reviews the proceedings of the 2015 Annual SPARTAN conference devoted to advances in spondyloarthritis.
The prevention of Herpes zoster infections can be challenging in patients receiving immunosuppressives or biologic therapies. Dr. Artie Kavanugh reviews a new, potential advance in vaccination for shingles.
The 4th annual IFPA meeting was held in Stockholm, Sweden on July 9-11, 2015. Leading experts discussed advances in research, therapy and patient care for psoriasis and psoriatic arthritis.
In this edition of “Across the Table”, Drs. Cush and Schwartman discuss uveitis. Our expert, Dr. Sergio Schwartzman offers up his approach to diagnosis and management.
Drug efficacy is swiftly proven in phase II and III trials. Yet drug safety requires time, wider exposure, physician education and patient acceptance to be fully established.
Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial.